Bimzelx vs Skyrizi
Bimekizumab vs Risankizumab · Comparison Guide
Quick Comparison
| Feature | Bimzelx | Skyrizi |
|---|---|---|
| Generic Name | Bimekizumab | Risankizumab |
| Manufacturer | UCB | AbbVie |
| Drug Class | IL-17A/F Inhibitor | IL-23 Inhibitor |
| Shared Conditions | Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis | |
Key Differences: Bimzelx vs Skyrizi
Bimzelx blocks both IL-17A and IL-17F; Skyrizi blocks IL-23 (upstream of IL-17). Both have shown high PASI 90/100 rates — Bimzelx demonstrated higher short-term clearance rates in some trials, while Skyrizi shows durable long-term control with less frequent dosing (every 12 weeks vs every 8 weeks for Bimzelx maintenance). Bimzelx has higher rates of oral candidiasis. Skyrizi is also approved for Crohn's disease.
💊 Bimzelx (Bimekizumab)
- Class: IL-17A/F Inhibitor
- Manufacturer: UCB
- Full Bimzelx information →
💊 Skyrizi (Risankizumab)
- Class: IL-23 Inhibitor
- Manufacturer: AbbVie
- Full Skyrizi information →
Bimzelx blocks both IL-17A and IL-17F; Skyrizi blocks IL-23 (upstream of IL-17). Both have shown high PASI 90/100 rates — Bimzelx demonstrated higher short-term clearance rates in some trials, while Skyrizi shows durable long-term control with less frequent dosing (every 12 weeks vs every 8 weeks for Bimzelx maintenance). Bimzelx has higher rates of oral candidiasis. Skyrizi is also approved for Crohn's disease.
Neither Bimzelx nor Skyrizi is universally better — the right choice depends on your specific condition, disease severity, insurance formulary, and health history. Your prescriber will determine which is most appropriate based on your clinical situation. BiologicHealthPlus carries both and can help you compare your coverage and costs for either medication.
Switching between biologics is common. Your prescriber will evaluate your current treatment response and determine if a switch is appropriate. BiologicHealthPlus can coordinate the transition including prior authorization for your new medication.
Both Bimzelx and Skyrizi are covered by most commercial insurance plans, Medicare Part D, and Medicaid with prior authorization. BiologicHealthPlus handles insurance verification and prior authorization for both medications at no charge. Most insured patients pay $0–$35/month through manufacturer copay programs.
Bimzelx and Skyrizi both have high cash list prices ($4,000–$9,000/month range) but most commercially insured patients pay $0–$35/month through manufacturer savings programs. BiologicHealthPlus automatically enrolls every patient in all available savings programs at no charge.
✅ BiologicHealthPlus Carries Both Bimzelx and Skyrizi
We handle insurance verification, prior authorization, copay enrollment, and free cold-chain delivery for both medications. Contact us and we'll help you understand your options and costs.
Medical Disclaimer: This comparison is for educational purposes only. The choice between Bimzelx and Skyrizi should be made by your healthcare provider based on your specific medical history, disease severity, and individual circumstances. Last updated: July 2026.